Pamiparib

Overview

Pamiparib (BGB-290) is an orally active, potent, highly selective PARP inhibitor, with IC 50 values of 0.9 nM and 0.5 nM for PARP1 and PARP2 , respectively. Pamiparib has potent PARP trapping, and capability to penetrate the brain, and can be used for the research of various cancers including the solid tumor.

Application

Products | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PARP

Product Information

• Catalog No.: HY-104044
• CAS No.: 1446261-44-4
• Molecular Formula: C16H15FN4O
• Molecular Weight: 298.32
• Purity: 99.96%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.25 mg/mL (7.54 mM); Clear solution
• Availability: In-stock

Source

Original product source